secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2023-12-07T23:59:59+00:00
Accession:  0001193125-23-290725
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Pharma appoints Michael Kalb as CFO; Alicia Grande to retire at year-end 2023
--------------------------------------------------------------------------------

- Alicia Grande to retire as CFO at end of 2023; will remain as consultant through Dec 31, 2024.
- Michael W. Kalb appointed EVP & CFO effective Jan 1, 2024; base salary $525k, bonus up to 50%, equity grant $3M.
- Dr. Steven Miller promoted to EVP, Chief Operating & Scientific Officer; Jeffrey Del Carmen to EVP, Chief Commercial Officer.
- Kalb has 30+ years pharma/finance experience, previously CFO of Impel, CinCor, and Amarin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312523290725/0001193125-23-290725-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312523290725/d418309d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-290725

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer